Rufang Xiang
No.197, Ruijin Er Road
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
1α,25(OH) 2D 3 prevents CD19 CAR-T cell exhaustion and differentiation via VDR-dependent transcriptional reprogramming.
Journal: Acta biochimica et biophysica Sinica
Published: December 11, 2025
Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 29, 2025
Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: August 14, 2025
Improved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion.
Journal: Frontiers in immunology
Published: November 20, 2024
Correction: Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway.
Journal: Cancer gene therapy
Published: October 21, 2024
A CD8+ T cell related immune score predicts survival and refines the risk assessment in acute myeloid leukemia.
Journal: Frontiers in immunology
Published: March 27, 2024
Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway.
Journal: Cancer gene therapy
Published: February 28, 2024
Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Journal: Cancer research
Published: July 05, 2023
Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: May 17, 2023
A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.
Journal: Cell reports. Medicine
Published: March 24, 2023
HIF-1α mediates CXCR4 transcription to activate the AKT/mTOR signaling pathway and augment the viability and migration of activated B cell-like diffuse large B-cell lymphoma cells.
Journal: Molecular carcinogenesis
Published: August 10, 2022
Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Journal: Chemotherapy
Published: March 06, 2021
Last Updated: 09/26/2026